227 results on '"Berg H"'
Search Results
2. Primary prophylaxis in children with severe haemophilia A and B—Implementation over the last 20 years as illustrated in real‐world data in the PedNet cohorts.
3. Reply to the letter of OʼMahoney et al.: Patient-reported outcome is not confined to HRQOL
4. Validation of the prediction model for inhibitor development in PUPs with severe haemophilia A
5. Assessments of outcome in haemophilia – what is the added value of QoL tools?
6. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A
7. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry
8. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors
9. Validation of the prediction score for inhibitor development in previously untreated patients (PUPs) with severe hemophilia A: PO-WE-105
10. Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: The RODIN study: PO-WE-103
11. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project
12. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients
13. Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry‐based study
14. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A
15. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors
16. Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment
17. Assessment of incidence of inhibitors in patients with haemophilia
18. A survey of adherence to haemophilia therapy in six European countries: results and recommendations
19. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up
20. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia
21. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
22. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors
23. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy
24. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors
25. Prophylaxis in children with severe haemophilia: when to start?: 23 S 701
26. Variation in antibody subclass pattern during immune tolerance therapy: 14 PO 431
27. FVIII gene mutation type, family history of inhibitors and the risk of inhibitor development in severe hemophilia A: the CANAL study: 14 PO 387
28. Intensity of treatment/prophylaxis and the risk to develop inhibitors among previously untreated patients with severe hemophilia: the CANAL Study: 14 PO 386
29. Age at first exposure and the risk of inhibitor development among previously untreated severe hemophilia A patients: the CANAL Study: 14 FP 362
30. Circumstantial risk factors for inhibitor development: 14 S 357
31. Ten years experience with a plasma derived monoclonal purified factor VIII concentrate: 05 PO 106
32. Pain and functional limitations in patients with severe haemophilia
33. Measuring patientsʼ perceptions on their functional abilities: validation of the Haemophilia Activities List
34. The use of a disability model in haemophilia research
35. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed
36. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters
37. Hepatitis C infection in children with haemophilia: a pilot study
38. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List
39. Development of a hemophilia-specific activities questionnaire: an update
40. Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis
41. In vivo recovery and safety of human factor VIII product AAFACT® in patients with haemophilia A
42. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
43. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome
44. Intermittent infusion of recombinant factor VIIa
45. Immune response in early infancy
46. Natural history of hepatitis C in haemophiliacs infected before the age of 18 years
47. Towards a haemophilia activities list (HAL)
48. Complications of port-a-cath (PAC) in children with severe haemophilia
49. Blood-induced joint damage: induction of chondrocyte apoptosis after short-term exposure of blood to cartilage
50. Blood-induced joint damage: ex vivo animal data on differences between immature and mature cartilage matrix turnover
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.